![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Showing 2 trials matching your filters.
Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström's Macroglo... Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib...
This study will evaluate the safety and efficacy of the BCL2 inhibitor BGB-11417 (sonrotoclax) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previousl...
DRUG: BGB-11417
DRUG: Zanubrutinib
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of c...
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
PROCEDURE: Computed Tomography
DRUG: Ibrutinib
PROCEDURE: Positron Emission Tomography
BIOLOGICAL: Rituximab
DRUG: Venetoclax
Your Source for Expert Insights & Support in Waldenström's Macroglobulinemia.
By subscribing to the Healthtree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2025 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811